Celyad Oncology - ADR

NASDAQ:CYAD  
4.82
-0.12 (-2.43%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Celyad Oncology - ADR Stock, NASDAQ:CYAD

Axis Business Park, rue Edouard Belin 2, Mont-Saint-Guibert, Walloon Region 1435
Belgium
Phone: +32.10.039.41.00
Number of Employees: 92

Description

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.